Company profile for Adicet Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Harnessing the power of the immune system to treat cancer and other diseases Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge allogeneic immunotherapies for cancer and other diseases. Adicet is developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors (CARs) or T Cell Receptors (TCR...
Harnessing the power of the immune system to treat cancer and other diseases Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge allogeneic immunotherapies for cancer and other diseases. Adicet is developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors (CARs) or T Cell Receptors (TCRs). Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating TCR-like MAbs (TCRLs) directed to these cancer-specific peptide targets.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
200 Constitution Drive Menlo Park, CA 94025
Telephone
Telephone
(650) 542-0034
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251128794647/en/Adicet-Bio-Reports-Inducement-Grant-under-Nasdaq-Listing-Rule-5635c4

BUSINESSWIRE
28 Nov 2025

https://www.businesswire.com/news/home/20251105901973/en/Adicet-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Updates

BUSINESSWIRE
05 Nov 2025

https://www.businesswire.com/news/home/20251031278051/en/Adicet-Bio-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635c4

BUSINESSWIRE
31 Oct 2025

https://www.businesswire.com/news/home/20251028026101/en/Adicet-Bio-to-Participate-in-a-Fireside-Chat-at-the-Guggenheim-2nd-Annual-Healthcare-Innovation-Conference

BUSINESSWIRE
28 Oct 2025

https://www.pharmiweb.com/press-release/2025-10-16/adicet-bio-announces-first-patient-dosed-in-phase-1-clinical-trial-of-adi-001-in-treatment-refractor

PHARMIWEB
16 Oct 2025

https://www.pharmiweb.com/press-release/2025-10-07/adicet-bio-inc-announces-80-million-registered-direct-offering

PHARMIWEB
07 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty